Slide 1: Q2 Investor Presentation August 2025
Q2 Investor Presentation August 2025
Slide 2: Disclosures: Forward-Looking Statements
Celanese Corporation Disclosures Forward-Looking Statements This presentation may contain "forward-looking statements," which include information concerning Celanese Corporation’s (the “Company”) plans objectives, goals, strategies, future revenues, cash flow, financial performance, synergies, capit
Slide 3: Discussion Topics
Discussion Topics 3 Earnings update Key actions and near- term imperatives
Slide 4: Q2 2025 Highlights
Q2 2025 Results Q2 2025 Results 4 Q2 2025 Highlights * Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations to comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and
Slide 5: Q3 2025 Outlook
Q3 ADJUSTED EPS* GUIDANCE $1.10 – $1.40 Q3 ADJUSTED EBIT* GUIDANCE BY BUSINESS SEGMENTS ACETYL CHAIN ENGINEERED MATERIALS $195 - $215 M $170 - $190 M Continued emphasis on cost reduction initiatives across both businesses Sequential improvement in AC earnings driven by lower turnaround expense Actio
Slide 6: Near Term Cost Reductions
$80 $10 $25 $15 $30 - $50 $20 - $30 Actions expected to deliver $120M cost savings in 2025, with future incremental opportunities of $50M - $100M 6 Near Term Cost Reductions Engineered Materials Complexity Reduction Targeted Productivity $80 - $90 million of targeted annualized savings primarily thr
Slide 7: Strong free cash flow performance and FY2025 target
2024 2025 Key actions expected to deliver higher YoY Free Cash Flow* despite lower demand environment 7 ~40% - ~60 % Strong free cash flow* performance $311 million in Q2 2025 1H 2025 free cash flow* is higher YOY by ~80% On track to achieve our target of $700 to $800 million FY2025 free cash flow*
Slide 8: Action plans driving management of near-term uncertainty
Celanese action plans and strong business fundamentals driving management of near-term uncertainty 8 INCREASE CASH FLOW INTENSIFY COST IMPROVEMENT DRIVE TOP LINE GROWTH to deleverage the balance sheet through supercharging the pipeline & strategic opportunities by maximizing productivity everyday En
Slide 9: Global leader in attractive growth markets
Global leader in attractive growth markets The Acetyl Chain offers multiple highly differentiated, long-term value creation levers 9 Advantaged cost position with strong presence in Western Hemisphere Established stable base of contracted business Unique integrated global product chain with optional
Slide 10: Global Acetyls leader with an integrated value chain
Competitor 1 Competitor 2 Competitor 3 Competitor 4 Competitor 5 Competitor 6 CO2 Methanol Acetic Acid Acetate Tow VAM Emulsions Powders 3 Global Acetyls leader with an integrated value chain 10 Peer data from public company filings; 1 EMEA – Europe, Middle East and Africa; 2 Captive only Significan
Slide 11: AC western hemisphere presence minimizes impact of China over-supply
AC western hemisphere presence in acetic acid and VAM helps minimize further impacts of industry over-supply in China 11 Asia drives recent AC declines in revenue and corresponding declines in earnings, while western hemisphere has remained stable Overcapacity in China remains largely in Asia; CE U.
Slide 12: Stability of the western hemisphere business supported by contracts
65% 70% 2021-2022 2023-2025 The stability of the western hemisphere business is supported by contractual positions 12 → Industry leading reliability makes AC a preferred partner for customers → Strategic contracts provide strong foundation and stable margins → Well positioned for demand recovery AC
Slide 13: Acetyl Chain model positioned to drive downstream growth
Acetyl Chain model is well positioned to drive downstream growth 13 DerivativesAcid + VAM % Revenue, 2024-25 2020 2021 2023 20242022 CLEAR LAKE VAM EXPANSION RDP ACQUISITION CLEAR LAKE ACID EXPANSION CARBON CAPTURE AND UTILIZATION RDP DEBOTTLENECK EMULSIONS DEBOTTLENECK EMULSIONS EXPANSION EVA EXPAN
Slide 14: EM offers an industry leading portfolio of polymer solutions
EM offers an industry leading portfolio of polymer solutions 14 LCP PPS PPA PCT LCPA PA 66 PA 6 PET PBT POM LFRT UHMWPE PP EVA AEM TPC TPV SBC CA Vectra® | Zenite® Fortron® Frianyl® XT | Celanyl® XT | Zytel® Thermx® Zytel® Frianyl® | Celanyl® | Zytel® Frianyl® | Celanyl® | Zytel® Impet® | Rynite® |
Slide 15: High Impact Programs drive EM growth
Created EM earnings stabilizing in a low demand environment… High Impact Programs (HIPs) drive EM growth … while HIPs continue to gain momentum 15 Top four High Impact Program segments Average Value per Project – 1H 2025 $144 $126 $214 Q4 24 Q1 25 Q2 25 Q3 25 EM Adjusted EBIT* ($M) MedicalAuto EV El
Slide 16: EM working capital reduction contributes to free cash flow
EM working capital reduction contributes to free cash flow* in 2025 with further opportunities in 2026+ 16 31% 29% 30% 0.15 0.2 0.25 0.3 0.35 0.4 0.7 0.9 1.1 1.3 1.5 1.7 1.9 2.1 2.3 2022 2023 2024 2025 TARGET 27-28% Inventory as % of Sales Strong focus on inventory reduction, leveraging multiple dri
Slide 17: Opportunistic and prudent refinancing
Opportunistic and prudent refinancing Maintain ample liquidity Excess cash + $1.75 B revolver (currently undrawn) Maintain flexibility via prepayable debt Continually optimize blended borrowing cost across all debt Resilient businesses are generating cash, aligning debt maturities with cash flow gen
Slide 18: Additional actions to drive towards $2 adjusted EPS
Q1 2025 Q2 2025 Q3 2025 Relentless focus on additional actions to drive earnings towards $2 adjusted earnings per share* Quarterly Adjusted EPS* 18* Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations
Slide 19: Celanese Offers a Compelling Investment Opportunity
Celanese Offers a Compelling Investment Opportunity Our mission is to position Celanese as a top quartile company for total shareholder return by delivering earnings growth in any environment 19 Leadership driving change Actions underway to deliver near-term earnings improvement Strong earnings leve
Slide 20: Upcoming Investor Relations Events
Upcoming Investor Relations Events 20 Sept 3 UBS Global Materials Conference, New York Sept 10 Morgan Stanley Conference, Laguna Beach Sept 9 Alembic Global, Torrey Pines Sept 16 RBC Conference, New York Aug 13 Mizuho Industrials Conference, New York